This symposium included three presentations with the aim to address the broad-spectrum treatment of schizophrenia. First, Professor Stephen Stahl addressed the early treatment of schizophrenia explaining the mechanism of action of dopamine partial agonists. During the second lecture, Professor Stefan Leucht discussed the role of our product in relapse, remission, and recovery. Finally, Professor Peter Falkai looked at how to address the needs of patients in the later stages of schizophrenia.
The most recent research on polypharmacy approaches in the treatment of schizophrenia was presented. Experts from across the globe outlined the conceptual basis for a rational, safe and evidence-based polypharmacy approach for schizophrenia, with talks from Professors Christian Schmidt-Kraepelin, Oliver Freudenreich, Mathias Zink and Alex Hofer
SHOULD SCHIZOAFFECTIVE DISORDER BE DIAGNOSED CROSS-SECTIONALLY (IDC-11) INSTEAD OF LONGITUDINALLY (DSM-5)?
In this Live debate event, the question whether schizoaffective disorder should be diagnosed cross-Sectionally (ICD-11) instead of longitudinally (DSM-5) was discussed. Professor Peter Falkai argued in support of the statement, while Professor Ingrid Melle formed the opposition. The debate was moderated by Professor Silvana Galderisi.
Speakers sought to provide an up-to-date analysis of the effectiveness and applicability of this technique in schizophrenia patients. With talks by Professors Antonio Vita, Merete Nordentoft, Rafael Penadés and Til Wykes, cognitive dysfunctions, a core feature of schizophrenia were considered in relation to the efficacy of cognitive remediation interventions.
PREDICTING THE OUTCOMES IN PSYCHOSIS: RECENT ADVANCES IN MOLECULAR PROFILING, NEUROIMAGING AND MACHINE LEARNING
This session included three presentations about recent advances to aid the prediction of outcomes in psychosis, considering a range of tools, from neuroimaging and machine learning to developments in metabolomics and lipidomics for schizophrenia prognosis.
This LIVE ECP symposium aimed to present the most recent research on personalised psychiatry and clinical evidence, bringing together international experts in all major areas of personalised psychiatric medicine.
STATE OF THE ART: THE CLINICAL CHARACTERISATION OF THE PATIENT WITH PRIMARY PSYCHOSIS AIMED AT PERSONALISATION OF MANAGEMENT
Aiming to address the shortcomings of current psychosis management strategies and identify ways to tackle them, Professor Maj explained why he sees personalised, individual management as the way forward in primary psychosis care.
This symposium addressed two important components of early intervention aiming at improving functional outcomes in schizophrenia and other psychotic disorders, namely timely assessment and treatment.
IMPROVING REAL-LIFE FUNCTIONING IN PEOPLE WITH SCHIZOPHRENIA: FROM ASSESSMENT TO INTEGRATED TREATMENT PLANS
This symposium, consisting of four lectures, presented data in chronic and first-episode patients on predictors of clinical and functional outcomes, along with perspectives on personalised and integrated management programmes in subjects with schizophrenia and high-risk statu
THE COMPLEX INTER-RELATIONSHIPS BETWEEN THERAPEUTIC INTERVENTIONS, NEUROANATOMY AND COGNITION IN MAJOR PSYCHOSES
Three distinguished speakers attempt to disentangle the complex inter-relationships between treatment, neuroanatomy, psychopathology and cognition in major psychoses, with the long-term goal of improving response and quality of life in this patient group.